CSL to Buy Novartis Influenza-Vaccine Unit for $275 Million

Blood products and vaccine maker CSL Ltd. agreed to buy Novartis AG’s influenza-vaccine business for $275 million, as the Australia-based company continues its global expansion.



from WSJ.com: US Business http://ift.tt/1xvRHLc

via IFTTT